Have a personal or library account? Click to login
The evolving role of PARP inhibitors in advanced ovarian cancer Cover

The evolving role of PARP inhibitors in advanced ovarian cancer

Forum of Clinical Oncology
Volume 12 (2021): Issue 1 (May 2021)
By: Sofia Levva,  Aglaia Skolariki,  Eleni Sogka,  Alexandros Bokas,  Avraam Assi,  Marianna K. Pispirigou and  Panagiotis Koliou  
Open Access
|Aug 2021

Authors

Sofia Levva

dr.slevva@gmail.com

Oncology Department, Bioclinic Private Hospital, Thessaloniki, Greece

Aglaia Skolariki

Department of Medical Oncology, Papageorgiou General Hospital, Thessaloniki, Greece

Eleni Sogka

Department of Medical Oncology, Papageorgiou General Hospital, Thessaloniki, Greece

Alexandros Bokas

1st Department of Medical Oncology, Theagenion Hospital, Thessaloniki, Greece

Avraam Assi

2nd Department of Medical Oncology, Henry Dunant Hospital Center, Athens, Greece

Marianna K. Pispirigou

Division of Oncology, Department of Internal Medicine, University Hospital of Patras, Greece

Panagiotis Koliou

Royal Surrey NHS Foundation Trust, Guildford, United Kingdom
DOI: https://doi.org/10.2478/fco-2021-0002 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 82 - 104
Submitted on: Jan 2, 2021
|
Accepted on: Feb 18, 2021
|
Published on: Aug 9, 2021
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
ovarian cancer,
PARP inhibitors,
BRCA mutation,
maintenance treatment,
resistance mechanisms,
homologous recombination deficiency
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2021 Sofia Levva, Aglaia Skolariki, Eleni Sogka, Alexandros Bokas, Avraam Assi, Marianna K. Pispirigou, Panagiotis Koliou, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 12 (2021): Issue 1 (May 2021)